U.S. Congestive Heart Failure Drugs Market Size & Outlook
U.S. congestive heart failure drugs market, 2018-2030 (US$M)
Related Markets
U.S. congestive heart failure drugs market highlights
- The U.S. congestive heart failure drugs market generated a revenue of USD 2,105.8 million in 2021 and is expected to reach USD 6,745.0 million by 2030.
- The U.S. market is expected to grow at a CAGR of 13.8% from 2022 to 2030.
- In terms of segment, ace inhibitors was the largest revenue generating drug type in 2021.
- Other Drug Types (Statins, including pipeline) is the most lucrative drug type segment registering the fastest growth during the forecast period.
Congestive heart failure drugs market data book summary
| Market revenue in 2021 | USD 2,105.8 million |
| Market revenue in 2030 | USD 6,745.0 million |
| Growth rate | 13.8% (CAGR from 2021 to 2030) |
| Largest segment | Ace inhibitors |
| Fastest growing segment | Other Drug Types (Statins, including pipeline) |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone antagonists, Inotropes, Other Drug Types (Statins, including pipeline) |
| Key market players worldwide | Bayer AG, Novartis AG ADR, Merck & Co Inc, AstraZeneca PLC ADR, Bristol-Myers Squibb Co, Amgen Inc, Boehringer Ingelheim, Pfizer Inc, Johnson & Johnson, Otsuka Pharmaceutical, Eli Lilly and Co, Novo Nordisk A/S ADR |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.2% of the global congestive heart failure drugs market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. congestive heart failure drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 770.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Congestive Heart Failure Drugs Market Scope
Congestive Heart Failure Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. congestive heart failure drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to congestive heart failure drugs market will help companies and investors design strategic landscapes.
Ace inhibitors was the largest segment with a revenue share of 32.88% in 2021. Horizon Databook has segmented the U.S. congestive heart failure drugs market based on ace inhibitors, angiotensin 2 receptor blockers, beta blockers, diuretics, aldosterone antagonists, inotropes, other drug types (statins, including pipeline) covering the revenue growth of each sub-segment from 2018 to 2030.
- U.S. Congestive Heart Failure Drugs Drug Type Outlook (Revenue, USD Million, 2018-2030)
- ACE Inhibitors
- Angiotensin 2 Receptor Blockers
- Beta Blockers
- Diuretics
- Aldosterone antagonists
- Inotropes
- Other Drug Types (Statins, including pipeline)
- U.S. Congestive Heart Failure Drugs Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to U.S. congestive heart failure drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. congestive heart failure drugs market databook
-
Our clientele includes a mix of congestive heart failure drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. congestive heart failure drugs market, including forecasts for subscribers. This country databook contains high-level insights into U.S. congestive heart failure drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. congestive heart failure drugs market report size, by drug type, 2018-2030 (US$M)
U.S. Congestive Heart Failure Drugs Market Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
